Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole plus palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study

被引：0
|
作者：
Hurvitz, Sara A.
Quiroga, Vanesa
Park, Yeon Hee
Bardia, Aditya
Lopez-Valverde, Vanesa
Steinseifer, Jutta
Fernando, Tharu M.
Spera, Gonzalo
Xue, Cloris
Fasching, Peter A.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-06
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Randomized Phase III Study of Amcenestrant Plus Palbociclib Versus Letrozole Plus Palbociclib in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Primary Results From AMEERA-5
    Cortes, Javier
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Delaloge, Suzette
    Iwata, Hiroji
    Rugo, Hope S.
    Neven, Patrick
    Kanagavel, Dheepak
    Cohen, Patrick
    Paux, Gautier
    Cartot-Cotton, Sylvaine
    Stefanova-Urena, Maya
    Deyme, Laure
    Aouni, Jihane
    Sebastien, Bernard
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [42] Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study
    Layman, Rachel M.
    Han, Hyo S.
    Rugo, Hope S.
    Stringer-Reasor, Erica M.
    Specht, Jennifer M.
    Dees, Claire
    Kabos, Peter
    Suzuki, Samuel
    Mutka, Sarah C.
    Sullivan, Brian F.
    Gorbatchevsky, Igor
    Wesolowski, Robert
    LANCET ONCOLOGY, 2024, 25 (04): : 474 - 487
  • [43] Open-label Phase II study of everolimus plus endocrine therapy in postmenopausal women with ER-positive and HER2-negative metastatic breast cancer (Chloe trial)
    Shimoi, Tatsunori
    Shimomura, Akihiko
    Shien, Tadahiko
    Uemura, Yukari
    Kato, Hiroaki
    Kitada, Masahiro
    Toyama, Tatsuya
    Aihara, Tomohiko
    Mukai, Hirofumi
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2018, 10 : 13 - 18
  • [44] A short-term neoadjuvant pilot study comparing exemestane and letrozole in postmenopausal women with estrogen receptor-positive HER2-negative breast cancer
    Miura, Daishu
    Iwatani, Tsuguo
    Kawabata, Hidetaka
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] OOTR-N007: A phase II neoadjuvant study of letrozole plus palbociclib in postmenopausal patients with ER positive, HER2 negative breast cancer
    Chow, Louis W. C.
    Lam, Chi-Kei
    Loo, Wings T. Y.
    CANCER RESEARCH, 2015, 75
  • [46] Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
    Ottestad, Lars
    Fronth, Line
    Rajendiran, Sajitha
    Aksnes, Liv Hege
    Eikesdal, Hans Petter
    Blix, Egil Store
    Ewertz, Marianne
    ACTA ONCOLOGICA, 2019, 58 (03) : 385 - 387
  • [47] Optimal duration of neoadjuvant exemestane treatment in elderly women with estrogen receptor-positive/HER2-negative breast cancer
    Takei, H.
    Saito, T.
    Ishikawa, Y.
    Hayashi, Y.
    Kurosumi, M.
    Kai, T.
    Tabei, T.
    BREAST, 2011, 20 : S75 - S75
  • [48] A phase II trial of nivolumab plus palbociclib plus anastrozole in postmenopausal women with ER+/HER2-primary breast cancer: CheckMate 7A8
    Tolaney, S. M.
    Jerusalem, G.
    Salgado, R.
    Liu, X.
    Chen, T.
    Zhang, H.
    Roberts, M.
    Zardavas, D.
    Prat, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S60 - S60
  • [49] A randomized, open-label, multicentre, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy based treatment strategy in patients with hormone receptor positive/HER2-negative metastatic breast cancer in a real world setting
    Loibl, Sibylle
    Barinoff, Jana
    Seiler, Sabine
    Decker, Thomas
    Denkert, Carsten
    Luebbe, Kristina
    Furlanetto, Jenny
    Mueller, Volkmar
    Mundhenke, Christoph
    Schmidt, Marcus
    Von Minckwitz, Gunter
    Uhlig, Mathias
    Burchardi, Nicole
    Thill, Marc
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial
    Ignatiadis, M.
    Brandao, M.
    Maetens, M.
    Ponde, N.
    Martel, S.
    Drisis, S.
    Veys, I.
    Mazy, S.
    Bollue, E.
    Neven, P.
    Duhoux, F. P.
    Chapiro, J.
    Awada, A. H.
    Besse-Hammer, T.
    Paesmans, M.
    Piccart, M.
    Vuylsteke, P.
    Sotiriou, C.
    ANNALS OF ONCOLOGY, 2018, 29
12345